Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: P.M.Freedman who wrote (1039)	6/13/1999 10:30:00 AM
From: William Partmann	Respond to of 1686

P.M. You have far too much information to be a casual daytrader. Let me see, once upon a time, X company of Wall Street looks at the world of drugs. They conclude that there is a cyclical shift away from drugs. Ah, but one of two has held up extremely well. And one was BGEN. Quickly they do a position paper on the company. Conclusion, it's over-exended, trading at an inflated PE. It will sell-off. Therefore, X company shorts BGEN. Perhaps they bet big. However, BGEN does not fall. So at the next meeting they decide to talk this stock down. Go forth to the media and proclaim the problems of this stock. And all the little minions go out a spread the information found in the position paper to those waiting feast upon financial news. Now this is a fairytale, but I don't trust you. It has nothing to do with your bearish attitude. Simply, I find you disingenuous. Though you profess differently, your only interest appears to be on the short side. Your posts are calculated to cause concern. The bears that I respect are up-front. You have every right to post on this board. You obviously are intelligent and your posts are of interest. That does not mean that I have to assist you. No reply in necessary. Good luck in your trading (other than BGEN). Bill

To: P.M.Freedman who wrote (1039)	6/13/1999 12:01:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

My current understanding of the state of Biogen's pipeline: 1. VLA4 (Asthma II, MS, Diabetes, RA) 2. Amevive (Psoraisis III this summer) 3. Antova (Lupus erythematosus II, ITP II, transplantation II, diabetes) 4. Adentri (edema assoc. w/Congestive Heart Failure) 5. Gelsolin (Cystic Fibrosis II) 6. Avonex (MS IV, basil cell carcinoma III, cervical dyspl.III, diffuse warts III) 7. Preclinical drug (?, ?) 8. Hirulog (pretty much dead, but TMC is pursuing anticoag w/angioplasty appl.) For PMF: both Amevive and Antova are likely to play a more prominent role for Biogen in the near future than Avonex. I would guess VLA4 will also be more important. Good trading.